Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 June 2025 | Story Andre Damons | Photo Andre Damons
Prof Matlalepula Matsabisa
Prof Motlalepula Matsabisa, renowned African Traditional Medicine expert and pharmacology researcher from the University of the Free State (UFS) will co-chair the World Health Organisation Global Traditional Medicine Summit steering committee.

Prof Motlalepula Matsabisa, renowned African Traditional Medicine expert and pharmacology researcher from the University of the Free State (UFS) has recently been elected a co-chairperson of the World Health Organisation (WHO) Global Traditional Medicine Summit steering committee. The other co-chairperson is Dr Goh Cheng Soon from Malaysia. 

The steering committee, which is appointed for one year, will help the WHO to organise the WHO Traditional Medicines Global Summit taking place later this year in New Delhi, India. The steering committee is also an advisory body to the WHO and the Global Traditional Medicine Centre to provide reviews and recommendations for the WHO Traditional Medicine Global Summit coordination, propose summit sessions and session speakers. This committee has 15 members from South Africa, Malaysia, Saudi Arabia, Ghana, India, China, Bhutan, Germany, Brazil, Egypt, New Zealand, US, Netherlands, Switzerland and Bolivia.

Prof Matsabisa, Research Director of the African Medicines Innovations and Technologies Development (AMITD) platform at the UFS, is also the chairperson of the WHO Africa Regional Expert Advisory Committee on Traditional Medicine (REACT)

 

Responsibility of the committee 

“Once more this is an honour for me to take this task and lead a group of experts – not just from the African continent where I am currently the chairperson of the WHO Afro REACT committee, but now I chair experts from all the continents and all six WHO geographical regions – namely Africa (Afro), the Americas (AMRO), the eastern Mediterranean (EMRO), Europe (EURO), South East Asia (SEARO) and the Western Pacific (WPRO). I chair a worldwide group of experts,” says Prof Matsabisa. 

According to him, the committee will work with WHO to design the summit programme, identify summit sessions and session speakers, as well as recommend ministers to be in the round-table discussions. The committee will also be responsible for the design of the exhibitions that will showcase traditional medicine products and practices across all six WHO regions. The identification of the sessions will be around action and delivery on the priority agenda from the past 2023 WHO Global summit as well as from the deliverables of the WHO 2025-2034 Traditional Medicines strategy. 

The theme for the WHO Traditional Medicines Global Summit is “Restoring balance for people and planet. The science and practice of health and well-being”. They anticipate attracting 6 000 people, from all over, to attend the summit with at least 1 000 in-person attendees and another 5 000 online participants. 

The committee will look at the first WHO 2023 Traditional Medicines Global summit and its Gujarat Declaration where the Traditional Medicine (TM) priority agenda was set – this priority agenda included global leadership, research and evidence, universal health coverage (UHC), primary health care (PHC) health systems, data and routine information systems, biodiversity and sustainability.

 

Market the UFS 

When a call for applications to serve on the steering committee went out, Prof Matsabisa applied and was later approached by the WHO to chair the steering and advisory committee. “I see this as an opportunity to serve the WHO and use my knowledge and skills to serve the world. I felt very honoured to have been approached for such an important job and role to undertake. As a chairperson, I will guide the committee, take responsibility for the planning and implementation of the summit. I will market the summit. I shall be the direct link between the WHO in Geneva and the committee.”

Prof Matsabisa indicated that he will use the chairmanship to market and internationalise the UFS AMITD programme and give it a further global outlook. He will also find new collaborators and potential funders and investors for projects and activities of the UFS and secure activities that will help find and fund global postdoctoral fellows and visiting scholars. This will be good for the AMITD platform.

“The steering committee shall set the 2nd WHO Traditional Medicine Global Summit theme for scale up learning, collaboration and action,” says Prof Matsabisa. “Therefore, the committee will design the summit programme to address these and take themes and discussions from high-level political commitments, building on UNGA, WHA, G20, BRICS, and AU etc. Launches of the WHO Global TM Library on Traditional Medicine; WHO Bulletin special issue on Traditional Medicine; TM Innovation and Investment Initiative; Global TM Research Roadmap; Global TM Data Network; and Learnings from Indigenous Knowledge will also take place.”

Furthermore, advancements of healthy ecosystems and TM integration and encouraging indigenous people's knowledge exchange; and AI and TM governance course/ brief as well as the advancing of cross-cutting frameworks for TM-related ethics, rights, IP, equitable access and benefits are on the agenda. 

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept